Request Demo

Last update 08 May 2025

Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

Private Company|2016|Guangdong Sheng, China

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

0 Patents (Medical) associated with Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

Literatures (Medical) associated with Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

01 Oct 2022·Analytical Biochemistry

Second near-infrared fluorescent dye for lateral flow immunoassays rapid detection of influenza A/B virus

Article

Author: Wang, Xiao ; Zhang, Runxuan ; Zhai, Hong ; Feng, Feng ; Yang, Di ; Liao, Tao ; Wang, Haiyan ; Wang, Xin

Sensitive and rapid diagnostic point of care testing (POCT) system is of great significance to prevent and control human virus infection. Here reported an immunochromatographic strip technology. The second near-infrared (NIR-II) fluorescent dye encapsulated into polystyrene (PS) nanoparticles, was integrated into a lateral flow assay platform to achieve excellent detection of influenza A/B. This surface-functionalized and mono-dispersed PS nanoparticles has been conjugated with influenza nucleoprotein monoclonal antibody as targets for influenza antigen-detection. This assay achieved the detection limit of 0.015 ng/mL for influenza A nucleoprotein and 4.3*10^-5 HAU/mL (10^2.08 TCID₅₀/mL) influenza A virus (influenza B: 0.037 ng/mL, 9.7*10^-7 HAU/mL (10^0.43 TCID₅₀/mL)). Compared with an Au-based lateral flow test strip, the strip's sensitivity is about 16-fold higher than it. Strip detection properties remain stable for 6 months under 4 °C to 30 °C storage. The assay's intra assay variation is 5.14% and the inter assay variation is 7.74%. Other potential endogenous and exogenous interfering substances (whole blood, nasal mucin, saliva, antipyretics, antihistamines and neuraminidase inhibitors) showed negative results, which verified the excellent specificity of this method. This assay was successfully applied to the POCT quantitative detection of influenza A/B virus, the sensitivity to influenza A and B viruses was 70% and 87.5% respectively, and the specificity was 100%. Therefore, these microspheres can be used as an effective material for rapid POCT detection in clinical specimens.

01 Aug 2022·Nano ResearchQ1 · MATERIALS SCIENCE

Sensitively detecting antigen of SARS-CoV-2 by NIR-II fluorescent nanoparticles

Q1 · MATERIALS SCIENCE

Article

Author: Ma, Rui ; Lin, Qihui ; Liang, Yongye ; Wang, Xinyuan ; Liao, Tao ; Wang, Guoxin ; Liu, Wenming ; Ren, Yan ; Hu, Ruibin

Early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an efficient way to prevent the spread of coronavirus disease 2019 (COVID-19). Detecting SARS-CoV-2 antigen can be rapid and convenient, but it is still challenging to develop highly sensitive methods for effective diagnosis. Herein, a lateral flow assay (LFA) based on fluorescent nanoparticles emitting in the second near-infrared (NIR-II) window is developed for sensitive detection of SARS-CoV-2 antigen. Benefiting from the NIR-II fluorescence with high penetration and low autofluorescence, such NIR-II based LFA allows enhanced signal-to-background ratio, and the limit of detection is down to 0.01 ng·mL^-1 of SARS-CoV-2 antigen. In the clinical swab sample tests, the NIR-II LFA outperforms the colloidal gold LFA with higher overall percent agreement with the polymerase chain reaction test. The clinical samples with low antigen concentrations (∼ 0.015-∼ 0.068 ng·mL^-1) can be successfully detected by the NIR-II LFA, but fail for the colloidal gold LFA. The NIR-II LFA can provide a promising platform for highly sensitive, rapid, and cost-effective method for early diagnosis and mass screening of SARS-CoV-2 infection.Electronic Supplementary MaterialSupplementary material (the operation procedure and cost of the materials needed of NIR-II lateral flow assays, the dynamic light scattering spectrum of the NIR-II nanoparticles, the components and testing principle, optimization of main parameters pertaining to the LFA performance, the colloidal gold LFA strip, the fluorescence intensity distribution curves and the T/C values of the strips for clinical samples by NIR-II LFA, and results of clinical swab samples detected by colloidal gold LFA) is available in the online version of this article at 10.1007/s12274-022-4351-1.

01 Aug 2022·Chemical Research in Chinese Universities

Plasmonic Gold Chip for Multiplexed Detection of Ovarian Cancer Biomarker in Urine

Author: Zeng, Linsheng ; Liao, Tao ; Wang, Guoxin ; Zeng, Zhongyi ; Yang, Qinglai ; Chen, Minwen

Human epididymal protein 4(HE4), carbohydrate antigen 125 (CA125) and osteopontin(OPN) are three key biomarkers in detecting ovarian cancer.To explore the diagnosis value of combined detection of these three biomarkers for ovarian cancer, we developed a multiplexed assay on a plasmonic gold(pGOLD) platform for measuring HE4, CA125 and OPN in urine.The receiver operator characteristic(ROC) curve was drawn, and the diagnosis values of each biomarker alone or in combination for ovarian cancer were evaluated.In the anal. to distinguish ovarian cancer from other gynecol. cancers, ovarian cysts and healthy people, the sensitivities of HE4, CA125 and OPN were 72.55%, 52.82% and 68.63%, the specificity values were 95.06%, 87.65% and 90.12%, while the areas under the curve(AUC) were 0.85, 0.75 and 0.77, resp.The sensitivity and specificity for combination detection of the three markers were 90.20% and 80.25%.The detection methods of HE4, CA125 and OPN based on plasma fluorescence enhanced chip showed good analytic and diagnostic performance, and provided a non-invasive method for the diagnosis of ovarian cancer.

100 Deals associated with Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

100 Translational Medicine associated with Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 20 Jul 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Huasi No Microorganism Technology (Shenzhen) Co., Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 20 Jul 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing